CD38

CD38 inhibitor 1 is an inhibitor of CD38. For hCD38 and mouse CD38, the IC50s are 7.3 nM and 1.9 nM.

Erzotabart, an IgG1-kappa monoclonal antibody targeting CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, cADPR1) in Homo sapiens, exhibits antineoplastic activity [1].

Felzartamab(MOR-202) is a human-targeted monoclonal antibody to CD38 for the study of multiple myeloma and advanced antibody-mediated rejection of allogeneic kidney transplants.

Isatuximab is a monoclonal antibody targeting the transmembrane receptor and extracellular enzyme CD38 in malignant cells of the hematological system and is a highly expressed protein in multiple myeloma. Isatuximab has antitumor activity, antibody-dependent cytotoxicity, complement-dependent cytotoxicity, and antibody-dependent cytophagocytosis, which can directly induce apoptosis in the absence of crosslinking. Isatuximab has an inhibitory effect on CD38 extracellular enzyme activity, which is associated with many cellular functions.

RBN013209 is a potent CD38 inhibitor. RBN013209 is useful in the treatment of cancer.

Luteolinidin chloride is a natural product. It is a potent CD38 inhibitor which can protect the heart against I/R injury with preservation of eNOS function and prevention of endothelial dysfunction in vivo.

CD38 Inhibitor 3 (compound 1), with an IC50 of 11 nM, is a potent agent that enhances mitochondrial biogenesis, diminishes lactate levels, and augments both NAD+ content and Nrf2 expression. In a Pus1 -/- mouse model of mitochondrial myopathy, it also elevates muscle function and bolstering exercise capacity [1].

MK-0159 is an orally available, highly potent CD38 inhibitor with myocardial injury protection for the study of cardiac ischemia and reperfusion injury.